Bazhenova, LyudmilaMinchom, AnnaViteri, SantiagoBauml, Joshua M.Ou, Sai-Hong IgnatiusGadgeel, Shirish M.Manuel Trigo, JoseBackenroth, DanielLi, TracyLondhe, AnilMahadevia, ParthivGirard, Nicolas2025-01-072025-01-072021-11-210169-5002https://hdl.handle.net/10668/27958Introduction: Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20 insertion (exon20ins) mutations have not been extensively studied. We conducted a retrospective cohort study to assess the clinical outcomes of EGFR exon20ins compared with common EGFR (cEGFR) mutations. Methods: Adults with advanced NSCLC harboring any EGFR mutations in the NSCLC Flatiron registry (2011 through May 2020) were included. To compare the relative prognosis (prognostic value) of exon20ins vs cEGFR, real-world overall survival (rwOS) was the primary endpoint. Separately, to compare the relative response to tyrosine kinase inhibitor (TKI) treatment (predictive value), real-world progression-free survival (rwPFS) was the primary endpoint. Results: For the prognostic value analysis, 3014 patients with EGFR mutant NSCLC (cEGFR, n = 2833; EGFR exon20ins, n = 181) were eligible. The median (95% CI) rwOS was 16.2 (11.04-19.38) months in the EGFR exon20ins cohort vs 25.5 (24.48-27.04) months in the cEGFR cohort (adjusted HR, 1.75 [1.45-2.131; penAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Non-small cell lung cancerAdvanced lung cancerEGFR mutationsEGFR exon 20 insertionsFlatiron registryCell lung-cancer1st-line treatmentOpen-labelCarboplatin-paclitaxelPhase-iiiChemotherapyAfatinibAdenocarcinomaGefitinibSurvivalresearch article34818606open access10.1016/j.lungcan.2021.10.0201872-8332http://www.lungcancerjournal.info/article/S0169500221005912/pdf724823600003